tiprankstipranks
Trending News
More News >
Cumberland Pharmaceuticals Inc (CPIX)
NASDAQ:CPIX
US Market
Advertisement

Cumberland Pharmaceuticals (CPIX) Earnings Dates, Call Summary & Reports

Compare
225 Followers

Earnings Data

Report Date
Mar 10, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
Last Year’s EPS
-0.14
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 04, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted strategic partnerships and international expansion, alongside strong revenue growth and clinical progress, which were slightly offset by shipment delays and increased competition. Overall, the sentiment of the call was positive, with more highlights than lowlights.
Company Guidance
During Cumberland Pharmaceuticals' third-quarter 2025 financial call, the company announced several key developments. They reported $8.3 million in combined revenues for their FDA-approved brands during the quarter, with year-to-date revenues reaching $30.9 million, marking a 12% increase over the same period last year. Cumberland introduced Talicia, a new addition to their commercial product portfolio, aimed at treating helicobacter pylori infections, with U.S. net sales totaling $8 million in 2024. They formed a joint venture with RedHill Biopharma to commercialize Talicia in the U.S., investing $4 million over two years and sharing net revenues equally. The company achieved international milestones with the launch of Vibativ in Saudi Arabia and regulatory approval of ibuprofen injection in Mexico. Cumberland also highlighted ongoing clinical programs, with ifetroban being evaluated in several trials, including Duchenne muscular dystrophy, systemic sclerosis, and idiopathic pulmonary fibrosis. Financially, they recorded a third-quarter adjusted loss of $0.8 million or $0.06 per share, but year-to-date adjusted earnings reached $1.9 million or $0.13 per share. Cumberland ended the quarter with $66 million in total assets, including $15 million in cash, and has reduced total debt by $10 million since the end of 2024.
Strategic Partnership with RedHill Biopharma
Cumberland entered into a partnership with RedHill Biopharma to commercialize Talicia, an FDA-approved treatment for helicobacter pylori infections, showing a high eradication rate exceeding 90%.
International Expansion
Cumberland launched Vibativ in Saudi Arabia and received regulatory approval for ibuprofen injection in Mexico, expanding its international footprint.
Strong Revenue Growth
Year-to-date revenue grew 12% over the same period last year, with total revenues reaching $30.9 million for the first nine months of 2025.
Positive Cash Flow
Cumberland reported a positive cash flow from operations, amounting to $5 million through September 2025.
Ifetroban Clinical Progress
Positive top-line results from the FIGHT DMD trial for ifetroban in Duchenne muscular dystrophy were reported, showing significant improvements in cardiac function.

Cumberland Pharmaceuticals (CPIX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CPIX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 10, 2026
2025 (Q4)
- / -
-0.136
Nov 04, 2025
2025 (Q3)
- / -0.13
-0.11-18.18% (-0.02)
Aug 05, 2025
2025 (Q2)
- / -0.05
-0.07735.06% (+0.03)
May 06, 2025
2025 (Q1)
- / 0.08
-0.138159.42% (+0.22)
Mar 04, 2025
2024 (Q4)
- / -0.14
-0.44469.37% (+0.31)
Nov 07, 2024
2024 (Q3)
- / -0.11
-0.074-48.65% (-0.04)
Aug 06, 2024
2024 (Q2)
- / -0.08
0.06-228.33% (-0.14)
May 07, 2024
2024 (Q1)
- / -0.14
0.013-1161.54% (-0.15)
Mar 05, 2024
2023 (Q4)
- / -0.44
-0.17-161.18% (-0.27)
Nov 07, 2023
2023 (Q3)
- / -0.07
-0.03-146.67% (-0.04)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CPIX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 04, 2025
$2.66$2.33-12.41%
Aug 05, 2025
$3.79$3.21-15.30%
May 06, 2025
$4.41$4.42+0.23%
Mar 04, 2025
$6.05$6.77+11.90%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cumberland Pharmaceuticals Inc (CPIX) report earnings?
Cumberland Pharmaceuticals Inc (CPIX) is schdueled to report earning on Mar 10, 2026, After Close (Confirmed).
    What is Cumberland Pharmaceuticals Inc (CPIX) earnings time?
    Cumberland Pharmaceuticals Inc (CPIX) earnings time is at Mar 10, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CPIX EPS forecast?
          Currently, no data Available
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis